MannKind Corporation

MNKD | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.50

-$0.04 (-1.13%)

At close: Sep 21, 2026, 4:00 PM ET

$3.60

+$0.10 (+2.86%)

Pre-market: Sep 22, 2026, 9:17 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.13%

(1D)

Rating

Updated: Sep 18, 2026

38.7

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $1.12B

1D Range

3.49 3.62

52W Range

2.23 6.51

Valuation (TTM)

PE -25

PB -16.64

EV/EBITDA 43.51

Valuation (NTM)

Forward PE 152.84

Forward PEG 0.22

Price Target $9

Cash Flow

FCF Yield -2.3%

SBC Adj. FCF Yield -4.4%

SBC Impact -91.6%

Margins

Gross Margin 75.7%

Operating Margin 2.0%

FCF Margin -6.6%

Growth (CAGR)

Revenue 3Y | 5Y 35.5% | 39.5%

Dil EPS 3Y | 5Y -4400.0% | 66.5%

FCF 3Y | 5Y -311.5% | 85.0%

Returns

ROA -6.0%

ROE 78.6%

ROIC 1.2%

Financial Health

Net Debt

$207.96M

Current Ratio 1.72

Interest Coverage 0.17

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine ...

Sector Healthcare

Industry Biotechnology

Employees 592

IPO Date Jul 27, 2004

Website www.mannkindcorp.com

Fiscal Year January - December

Full Company Profile

Latest News

4 days ago · marketbeat.com

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase 1b data for MNKD-201 in idiopathic pulmonary fibrosis, or IPF.

13 days ago · globenewswire.com

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

20 days ago · globenewswire.com

MannKind to Present at Upcoming Investor Conferences

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

25 days ago · zacks.com

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.

1 month ago · seekingalpha.com

MannKind: New Approvals Majorly Increase MannKind's Prospects

Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years.

2 months ago · seekingalpha.com

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

2 months ago · marketbeat.com

MannKind Q2 Earnings Call Highlights

MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs.

2 months ago · zacks.com

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

2 months ago · zacks.com

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind (MNKD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago.